Update on Taiwanese divestment
06 Feb 2024 08:00 CET
Nom de l'emetteur
NOVACYT
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Update on Taiwanese divestment
Paris, France, and Eastleigh and Manchester, UK - 6 February 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, has received formal notification from INEX Innovate Pte Ltd of its decision to terminate discussions regarding the acquisition of Yourgene Health Taiwan Co Ltd, as originally announced by Yourgene Health plc ("Yourgene") on 13 June 2023. As a result, Yourgene's Taiwanese laboratory business will remain part of the Novacyt Group.
The Board does not consider the divestment material and will continue to evaluate a number of options in relation to the future of the Taiwanese laboratory business that offer the best value to all stakeholders.
Contacts
| Novacyt SA | novacyt.com/investors | |||
| James McCarthy, Acting Chief Executive Officer | Via Walbrook PR | |||
| Steve Gibson, Chief Financial Officer | ||||
| SP Angel Corporate Finance LLP (Nominated Adviser and Broker) | +44 (0)20 3470 0470 | |||
| Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
||||
| Deutsche Numis (Joint Broker) | +44 (0)20 7260 1000 | |||
| Freddie Barnfield / Duncan Monteith / Michael Palser | ||||
| Allegra Finance (French Listing Sponsor) Rémi Durgetto / Yannick Petit |
+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com / y.petit@allegrafinance.com |
|||
| Walbrook PR (Financial PR & IR) Stephanie Cuthbert / Paul McManus / Phillip Marriage / Alice Woodings |
+44 (0)20 7933 8780 or novacyt@walbrookpr.com +44 (0)7796 794 663 / +44 (0)7980 541 893 +44 (0)7867 984 082 / +44 (0)7407 804 654 |
|||
About Novacyt Group (www.novacyt.com)
Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.
The Company is divided into three business segments:
| Clinical | Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas: · Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests · Precision Medicine: DPYD genotyping assay · Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel |
| Instrumentation | Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including: · Ranger® Technology: automated DNA sample preparation and target enrichment technology MyGo: real-time quantitative PCR (qPCR) instruments |
| Research Use Only | Range of services for the research industry: · Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry · Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES) |
Novacyt is headquartered in Vélizy in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
- SECURITY MASTER Key : xZpxlpmalW/Ky26ek8tpZ2WWmmZqk2PFamialmZxacuXaJ2TlG9iapXGZnFllWxu
- Pour contrôler cette clé : https://www.security-master-key.com.
Information réglementée :
Informations privilégiées :
- Autres communiqués
Communiqué intégral et original au format PDF : https://www.actusnews.com/news/84078-0836c.pdf
Source
NOVACYT
Fournisseur
ActusNewsWire
Company Name
NOVACYT
ISIN
FR0010397232
Symbole
ALNOV
Marché
Euronext Growth